Critical Role of Neutralizing Antibody for SARS-CoV-2 Reinfection and Transmission

Overview

Journal Emerg Microbes Infect

Specialty Infectious Diseases

Date 2021 Jan 7

PMID 33407005

Citations 42

Authors

Young-Il Kim

Se-Mi Kim

Su-Jin Park

Eun-Ha Kim

Kwang-Min Yu

Jae-Hyung Chang

Eun Ji Kim

Mark Anthony B Casel

Rare Rollon

Seung-Gyu Jang

Jihye Um

Min-Suk Song

Hye Won Jeong

Eung-Gook Kim

Yeonjae Kim

So Yeon Kim

Jun-Sun Park

Mi Sun Park

Geun-Yong Kwon

Sang Gu Yeo

Shin-Ae Lee

Youn Jung Choi

Jae U Jung

Young Ki Choi

Affiliations

Soon will be listed here.

Abstract

Cases of laboratory-confirmed SARS-CoV-2 reinfection have been reported in a number of countries. Further, the level of natural immunity induced by SARS-CoV-2 infection is not fully clear, nor is it clear if a primary infection is protective against reinfection. To investigate the potential association between serum antibody titres and reinfection of SARS-CoV-2, ferrets with different levels of NAb titres after primary SARS-CoV-2 infection were subjected to reinfection with a heterologous SARS-CoV-2 strain. All heterologous SARS-CoV-2 reinfected ferrets showed active virus replication in the upper respiratory and gastro-intestinal tracts. However, the high NAb titre group showed attenuated viral replication and rapid viral clearance. In addition, direct-contact transmission was observed only from reinfected ferrets with low NAb titres (<20), and not from other groups. Further, lung histopathology demonstrated the presence of limited inflammatory regions in the high NAb titre groups compared with control and low NAb groups. This study demonstrates a close correlation between a low NAb titre and SARS-CoV-2 reinfection in a recovered ferret reinfection model.

Citing Articles

Study on SARS-CoV-2 infection in middle-aged and elderly population infected with hepatitis virus: a cohort study in a rural area of northeast China.

Pan Y, Jia Z, Yu X, Lv H, Zhang Y, Wu Y PeerJ. 2025; 13:e19021.

PMID: 39995984 PMC: 11849502. DOI: 10.7717/peerj.19021.

Clinical and prognostic implications of hyaluronic acid in patients with COVID-19 reinfection and first infection.

Li Y, Han M, Li X Front Microbiol. 2024; 15:1406581.

PMID: 38881657 PMC: 11178136. DOI: 10.3389/fmicb.2024.1406581.

The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.

Chu J, Dai Q, Dong C, Kong X, Tian H, Li C Front Public Health. 2024; 12:1364048.

PMID: 38873290 PMC: 11169644. DOI: 10.3389/fpubh.2024.1364048.

RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.

Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C Vaccines (Basel). 2024; 12(1).

PMID: 38250853 PMC: 10818657. DOI: 10.3390/vaccines12010040.

SARS-CoV-2 infection in animals: Patterns, transmission routes, and drivers.

Fang R, Yang X, Guo Y, Peng B, Dong R, Li S Eco Environ Health. 2024; 3(1):45-54.

PMID: 38169914 PMC: 10758742. DOI: 10.1016/j.eehl.2023.09.004.

References

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

Kiyuka P, Agoti C, Munywoki P, Njeru R, Bett A, Otieno J . Human Coronavirus NL63 Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya. J Infect Dis. 2018; 217(11):1728-1739. PMC: 6037089. DOI: 10.1093/infdis/jiy098. View

Cao W, Liu W, Zhang P, Zhang F, Richardus J . Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007; 357(11):1162-3. DOI: 10.1056/NEJMc070348. View

Patel M, Thornburg N, Stubblefield W, Talbot H, Coughlin M, Feldstein L . Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. JAMA. 2020; 324(17):1781-1782. PMC: 7499233. DOI: 10.1001/jama.2020.18796. View

Chandrashekar A, Liu J, Martinot A, McMahan K, Mercado N, Peter L . SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020; 369(6505):812-817. PMC: 7243369. DOI: 10.1126/science.abc4776. View

Houser K, Broadbent A, Gretebeck L, Vogel L, Lamirande E, Sutton T . Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathog. 2017; 13(8):e1006565. PMC: 5574614. DOI: 10.1371/journal.ppat.1006565. View

Olsen C, Corapi W, Ngichabe C, Baines J, Scott F . Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol. 1992; 66(2):956-65. PMC: 240797. DOI: 10.1128/JVI.66.2.956-965.1992. View

Ibarrondo F, Fulcher J, Goodman-Meza D, Elliott J, Hofmann C, Hausner M . Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020; 383(11):1085-1087. PMC: 7397184. DOI: 10.1056/NEJMc2025179. View

10.

An J, Liao X, Xiao T, Qian S, Yuan J, Ye H . Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test. Ann Transl Med. 2020; 8(17):1084. PMC: 7575971. DOI: 10.21037/atm-20-5602. View

11.

Mercatelli D, Giorgi F . Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front Microbiol. 2020; 11:1800. PMC: 7387429. DOI: 10.3389/fmicb.2020.01800. View

12.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

13.

Kim Y, Kim S, Kim S, Kim E, Park S, Yu K . Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. Cell Host Microbe. 2020; 27(5):704-709.e2. PMC: 7144857. DOI: 10.1016/j.chom.2020.03.023. View

14.

Randolph H, Barreiro L . Herd Immunity: Understanding COVID-19. Immunity. 2020; 52(5):737-741. PMC: 7236739. DOI: 10.1016/j.immuni.2020.04.012. View

15.

Jeong H, Kim S, Kim H, Kim Y, Kim J, Cho J . Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin Microbiol Infect. 2020; 26(11):1520-1524. PMC: 7375961. DOI: 10.1016/j.cmi.2020.07.020. View

16.

Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B . Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020; 368(6494):1016-1020. PMC: 7164390. DOI: 10.1126/science.abb7015. View

17.

. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4):536-544. PMC: 7095448. DOI: 10.1038/s41564-020-0695-z. View

18.

Choe P, Perera R, Beom Park W, Song K, Bang J, Kim E . MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis. 2017; 23(7):1079-1084. PMC: 5512479. DOI: 10.3201/eid2307.170310. View

19.

Okba N, Muller M, Li W, Wang C, GeurtsvanKessel C, Corman V . Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020; 26(7):1478-1488. PMC: 7323511. DOI: 10.3201/eid2607.200841. View

20.

Kliks S, Nisalak A, BRANDT W, Wahl L, Burke D . Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989; 40(4):444-51. DOI: 10.4269/ajtmh.1989.40.444. View